Karyopharm Therapeutics (KPTI) Financials
$1.21
As on 29-Sep-2026 16:22EDT
Market cap
$37 Mln
Revenue (TTM)
$147 Mln
P/E Ratio
--
P/B Ratio
12
Div. Yield
0 %
Income Statement ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Operating Revenue
|
146.62
|
146.07
|
145.24
|
146.03
|
157.07
|
209.82
|
|||||
|
Cost of Revenue
|
6.04
|
5.95
|
6.01
|
4.94
|
5.21
|
3.40
|
|||||
|
Gross Profit
|
140.58
|
140.12
|
139.23
|
141.09
|
151.86
|
206.42
|
|||||
|
Operating Expenses
|
222.93
|
230.83
|
258.67
|
270.63
|
294.06
|
304.69
|
|||||
|
Operating Profit (EBIT)
|
-82.35
|
-90.71
|
-119.44
|
-129.54
|
-142.20
|
-98.27
|
|||||
|
Other Income
|
--
|
--
|
--
|
--
|
2.28
|
0.50
|
|||||
|
Profit before Tax
|
-224.77
|
-196.00
|
-76.37
|
-142.78
|
-164.92
|
-123.82
|
|||||
|
Provision for Tax
|
-0.03
|
0.04
|
0.06
|
0.32
|
0.37
|
0.27
|
|||||
|
Profit after Tax (Net Income)
|
-224.74
|
-196.04
|
-76.42
|
-143.10
|
-165.29
|
-124.09
|
|||||
|
Minority Interest
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Consolidated Profit
|
--
|
--
|
--
|
--
|
-165.29
|
-124.09
|
Liabilities ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Shareholder's Funds
|
-330.17
|
-292.93
|
-186.02
|
-136.21
|
-16.66
|
-79.67
|
|||||
|
Minority Interest
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Non-Current Liabilities
|
307.25
|
309.28
|
258.17
|
307.17
|
308.92
|
311.26
|
|||||
|
Current Liabilities
|
134.23
|
92.06
|
92.26
|
69.48
|
65.91
|
73.72
|
|||||
|
Total Liabilities
|
245.55
|
108.42
|
164.42
|
240.44
|
358.17
|
305.31
|
Assets ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Non-Current Assets
|
4.94
|
5.27
|
7.93
|
6.52
|
8.01
|
29.70
|
|||||
|
Current Assets
|
106.38
|
103.15
|
156.49
|
233.92
|
350.16
|
275.61
|
|||||
|
Total Assets
|
245.55
|
108.42
|
164.42
|
240.44
|
358.17
|
305.31
|
|||||
|
Total Debt*
|
215.89
|
233.61
|
194.52
|
177.02
|
179.07
|
180.58
|
|||||
|
Net Current Assets
|
-27.86
|
11.09
|
64.23
|
164.44
|
284.25
|
201.89
|
Cashflow ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cash From Operating Activities
|
--
|
-75.37
|
-127.49
|
-92.72
|
-149.55
|
-107.12
|
|||||
|
Cash Flow from Investing Activities
|
--
|
43.38
|
95.47
|
7.94
|
-104.26
|
141.84
|
|||||
|
Cash from Financing Activities
|
--
|
30.05
|
41.65
|
1.12
|
193.74
|
73.65
|
|||||
|
Net Cash Inflow / Outflow
|
--
|
--
|
--
|
--
|
-60.07
|
108.37
|
Financials Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Adjusted EPS ($)
|
-12.65
|
-10.76
|
-9.11
|
-18.70
|
-27.57
|
-21.43
|
|||||
|
Cash EPS ($)
|
--
|
-10.75
|
-9.07
|
-18.63
|
-27.47
|
-21.29
|
|||||
|
Adjusted Book Value ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Dividend per Share ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cash Flow per Share ($)
|
--
|
-4.14
|
-15.19
|
-12.12
|
-24.94
|
-18.49
|
|||||
|
Free Cash Flow per Share ($)
|
--
|
-4.14
|
-15.21
|
-12.12
|
-24.96
|
-19.48
|
Profitability Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
ROCE (%)
|
--
|
771.62
|
-309.92
|
-140.83
|
-125.54
|
-91.48
|
|||||
|
ROE (%)
|
--
|
81.86
|
47.43
|
187.23
|
343.18
|
852.05
|
|||||
|
ROA (%)
|
-99.96
|
-143.71
|
-37.75
|
-47.81
|
-49.83
|
-40.13
|
|||||
|
EBIT Margin (%)
|
-120.04
|
-102.79
|
-26.81
|
-81.46
|
-89.08
|
-46.60
|
|||||
|
Net Margin (%)
|
-153.28
|
-134.21
|
-52.62
|
-97.99
|
-103.73
|
-59.00
|
|||||
|
Cash Profit Margin (%)
|
0.00
|
--
|
--
|
--
|
--
|
--
|
Growth Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue Growth (%)
|
6.81
|
0.01
|
-0.01
|
-0.07
|
-0.25
|
0.94
|
|||||
|
EBIT Growth (%)
|
-123.46
|
-285.56
|
67.26
|
14.99
|
-43.11
|
42.09
|
|||||
|
Net Profit Growth (%)
|
-81.88
|
-156.52
|
46.60
|
13.43
|
-33.20
|
36.78
|
|||||
|
EPS Growth (%)
|
13.37
|
-0.18
|
0.51
|
0.32
|
-0.29
|
-7.05
|
|||||
|
Book Value Growth (%)
|
58.84
|
--
|
--
|
--
|
--
|
--
|
Valuation Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Price / Earnings
|
--
|
-0.68
|
-0.07
|
-0.05
|
-0.12
|
-0.30
|
|||||
|
Price / Book Value
|
12.05
|
-0.46
|
-0.03
|
-0.05
|
-1.22
|
-0.47
|
|||||
|
Dividend Yield (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
EV/EBITDA
|
-1.85
|
-2.03
|
-2.37
|
0.07
|
0.56
|
0.11
|
|||||
|
Close Price ($)
|
9.77
|
7.36
|
0.68
|
0.87
|
3.40
|
6.43
|
|||||
|
High Price ($)
|
10.99
|
10.38
|
1.95
|
4.87
|
14.73
|
18.00
|
|||||
|
Low Price ($)
|
3.65
|
0.51
|
0.58
|
0.62
|
2.45
|
4.42
|
|||||
|
Market Cap ($ Cr)
|
36.74
|
--
|
--
|
--
|
--
|
--
|
Solvency Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debt to Equity
|
-0.63
|
-0.80
|
-1.05
|
-1.30
|
-10.75
|
-2.27
|
|||||
|
Short term debt to equity ratio
|
0.00
|
-0.08
|
-0.13
|
-0.02
|
-0.17
|
-0.03
|
|||||
|
Current Ratio
|
0.79
|
1.12
|
1.70
|
3.37
|
5.31
|
3.74
|
|||||
|
Quick Ratio
|
0.76
|
1.08
|
1.64
|
3.32
|
5.25
|
3.68
|
|||||
|
Interest Coverage
|
-3.56
|
-3.27
|
-1.04
|
-4.99
|
-5.60
|
-3.75
|
Operating Efficiency Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debtors to sales (%)
|
20.37
|
17.92
|
21.18
|
18.46
|
29.98
|
10.72
|
|||||
|
Asset Turnover
|
0.65
|
1.07
|
0.72
|
0.49
|
0.47
|
0.68
|
|||||
|
Receivable days
|
--
|
71.20
|
72.59
|
92.60
|
80.90
|
30.79
|
|||||
|
Inventory Days
|
--
|
269.44
|
236.59
|
268.54
|
291.82
|
362.35
|
|||||
|
Payable days
|
--
|
279.66
|
250.21
|
217.88
|
153.30
|
324.94
|
|||||
|
Cash Conversion Cycle
|
--
|
60.97
|
58.97
|
143.27
|
219.42
|
68.21
|